 |
Jack Andraka15-year-old American schoolboy, winner of the 2012 Intel Science Fair
Country:
 USA |
Content:
- Jack Andraka - The Teenager Who Revolutionized Cancer Treatment
- A Surprising Breakthrough
- The Key Discovery
- Unmatched Sensitivity and Accuracy
- Future Applications
- Achievements and Future Plans
Jack Andraka - The Teenager Who Revolutionized Cancer Treatment
At just 15 years old, Jack Andraka, an American school student, became the winner of the 2012 Intel Science Fair. His groundbreaking research on a new method to treat pancreatic cancer earned him not only first place but also the prestigious Gordon E. Moore Award. Pancreatic cancer is considered one of the most dangerous diseases of our time, and despite significant advancements in medical treatments, finding a definitive solution has remained elusive.
A Surprising Breakthrough
In a surprising turn of events, Jack Andraka, a relatively unknown young scientist, delivered a significant blow to cancer research. Instead of presenting a typical science fair project, Andraka introduced a revolutionary method for treating pancreatic cancer. His creation, which consisted of a small sheet of ordinary filter paper, was coated with a solution of carbon nanotubes - hollow cylinders with walls as thin as an atom, covered with specialized antibodies. These nanotubes were capable of binding to specific viruses and proteins.
The Key Discovery
What made Andraka's project unique was his observation that the electrical conductivity of the nanotubes varied significantly as the distance between them changed. Additionally, when the nanotubes captured the targeted proteins, they shifted slightly, which could be detected using simple electrical measuring devices. Although Andraka used a basic $50 tester purchased from a nearby store, medical professionals would be able to employ more precise instruments.
Unmatched Sensitivity and Accuracy
In a blind test using 100 samples, Andraka's nanotube sensor successfully detected the presence of mesothelin, a protein traditionally used as a biological marker for pancreatic cancer. The protein was present in extremely low concentrations, no more than 0.156 nanograms per milliliter, a concentration nearly 100 times lower than normal levels. Furthermore, Andraka's invention demonstrated not only exceptional sensitivity but also incredible precision. The commonly used technique, known as the enzyme-linked immunosorbent assay (ELISA), was approximately 168 times slower, 267 times more expensive, and 400 times less sensitive than Andraka's sensor.
Future Applications
Andraka's sensor, costing only around $3 per unit, has the potential to identify dangerous proteins before cancer has a chance to establish itself in a patient's body. Each sensor can perform up to ten tests, with each test taking only five minutes. Moreover, beyond its use in cancer treatment, Andraka's invention is expected to analyze patients' resistance to different antibiotics and monitor the effectiveness of chemotherapy and radiation therapy.
Achievements and Future Plans
Currently, Andraka is in the process of obtaining a patent for his invention and plans to present his creation to the American Association for Cancer Research. He recently spoke before Congress, highlighting the importance of additional funding for pancreatic cancer research, a disease that currently claims approximately 94.5% of its victims. Andraka's groundbreaking work has attracted the attention of various private companies, with entrepreneurs eager to explore the potential of his new anti-cancer sensors.
